Li S, Zhu F, Waresi Abudourexiti, Wang Z Y, Chen M F, Guo Y Z, Yang Z R, Zhou Y, Gong J F
Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2025 Apr 25;28(4):374-383. doi: 10.3760/cma.j.cn441530-20240928-00330.
To investigate the clinical characteristics, postoperative complications, and risk factors for pouchitis in surgical patients with ulcerative colitis (UC). This was a retrospective observational study. The clinical data of 336 UC patients who had undergone surgical treatment at the Inflammatory Bowel Disease Center of the Department of General Surgery, Jinling Hospital Affiliated to Nanjing University Medical School from February 2014 to February 2024 were enrolled. The study patients were stratified into 2014-2019 ( = 158) and 2020-2024 groups ( = 178), these being the periods before and after biologics were covered for treatment of UC by national insurance in China in 2020. Clinical characteristics and surgical complications were analyzed and compared between the 2014-2019 and 2020-2024 groups. Multivariable logistic regression was performed to identify the risk factors associated with pouchitis in UC patients undergoing total proctocolectomy with ileal pouch-anal anastomosis (TPC-IPAA). The study cohort comprised 336 UC patients, 193 (57.4%) of whom were men. The median preoperative disease course was 48.0 months and the mean age at colectomy was 46.4±15.4 years. TPC-IPAA had been performed on 275 patients (81.8%), 129 in the 2014-2019 group and 146 in the 2020-2024 group. Sixty-one patients had undergone total or subtotal colectomy, 29 in the 2014-2019 group and 32 in the 2020-2024 group. 262 (78.0%) UC patients underwent surgery due to medical refractory. Ninety-nine (29.5%) had used biopharmaceuticals within 2 months prior to surgery, 63 (18.8%) of them having received infliximab. A smaller proportion of patients had undergone surgery for UC that was refractory to medications in the 2020-2024 group than in the 2014-2019 group (73.0% [130/178] vs. 83.5% [132/158], χ=5.384, =0.020), the patients were older at colectomy (48.0±15.4 years vs. 44.6±15.2 years, =-2.008, =0.045), the body mass index was higher (20.2±3.1 kg/m vs. 19.4±3.2 kg/m, =-2.201, =0.028), the Mayo score prior to surgery was lower ([, ]: 11.0 [9.2, 12.0 points] vs. 12.0 [11.0, 12.0) points, =-4.242, =0.001), the rate of Charlson Comorbidity Index ≥ 3 scores was higher (27.0% [48/178] vs. 17.1% [27/158], χ=5.384, =0.020), a greater percentage of patients had received biologics prior to surgery (41.0% [73/178) vs. 16.5% [26/158], χ=24.285, <0.001), and intraoperative blood loss was greater ([, ]: 100.0 [100.0, 150.0] ml vs. 50.0 [30.0, 100.0] ml, =-7.054, <0.001) despite the operation time being shorter (253.8±74.6 minutes vs. 315.2±96.8 minutes, =6.265, <0.001). Among the 275 patients undergoing TPC-IPAA, 95 (34.6%) had early complications (within 30 days after surgery), 20 (7.3%) of which were Clavien-Dindo Grade III-IV complications. Among these patients, 50 (18.2%) had ileus or small bowel obstruction, 11 in the 2014-2019 group and 39 in the 2020-2024 group; this difference is statistically significant (χ=15.225, <0.001). Ninety-one patients (33.1%) had late complications (more than 30 days after surgery), 75 (27.3%) being pouchitis (36 in the 2014-2019 group and 39 in the 2020-2024 group); this difference is not statistically significant (χ=0.049, =0.824). Five patients (1.8%) had undergone pouch excision with permanent ileostomy. Among the 61 patients who had undergone total or subtotal colectomy, 26 (42.6%) developed early postoperative complications, including 10 (16.4%) Clavien-Dindo Grade III-IV complications and one death (1.6%), the last being attributable to multiorgan dysfunction. Three patients (4.9%) had late complications; the difference in incidence of postoperative complications between the 2014-2019 and 2020-2024 groups is not statistically significant (both >0.05). Multivariable analysis identified intraoperative blood transfusion (OR: 2.12, 95% CI: 1.19-3.75, =0.010) and interval to stoma closure > 120 days (OR: 2.05, 95%CI: 1.16-3.62, = 0.013) as independent risk factors for development of pouchitis in UC patients undergoing TPC-IPAA. Surgical treatment of UC remains safe in the biologics era. Proactive strategies to reduce intraoperative blood transfusion and achieve timely stoma closure may reduce the risk of pouchitis in UC patients undergoing TPC-IPAA.
研究溃疡性结肠炎(UC)手术患者的临床特征、术后并发症及袋炎的危险因素。这是一项回顾性观察研究。纳入了2014年2月至2024年2月在南京大学医学院附属金陵医院普通外科炎症性肠病中心接受手术治疗的336例UC患者的临床资料。研究患者被分为2014 - 2019年组(n = 158)和2020 - 2024年组(n = 178),这分别是中国2020年国家医保覆盖UC生物制剂治疗前后的时间段。对2014 - 2019年组和2020 - 2024年组的临床特征和手术并发症进行分析和比较。进行多变量逻辑回归以确定接受全直肠结肠切除加回肠储袋肛管吻合术(TPC - IPAA)的UC患者发生袋炎的危险因素。研究队列包括336例UC患者,其中193例(57.4%)为男性。术前疾病病程中位数为48.0个月,结肠切除时的平均年龄为46.4±15.4岁。275例患者(81.8%)接受了TPC - IPAA,2014 - 2019年组129例,2020 - 2024年组146例。61例患者接受了全结肠或次全结肠切除术,2014 - 2019年组29例,2020 - 2024年组32例。262例(78.0%)UC患者因药物难治性而接受手术。99例(29.5%)在手术前2个月内使用过生物制剂,其中63例(18.8%)接受过英夫利昔单抗治疗。2020 - 2024年组因药物难治性UC接受手术的患者比例低于2014 - 2019年组(73.0% [130/178] 对83.5% [132/158],χ = 5.384,P = 0.020),结肠切除时患者年龄更大(48.0±15.4岁对44.6±15.2岁,t = -2.008,P = 0.045),体重指数更高(20.2±3.1 kg/m²对19.4±3.2 kg/m²,t = -2.201,P = 0.028),术前梅奥评分更低([中位数,四分位间距]:11.0 [9.2,12.0分] 对12.0 [11.0,12.0)分,t = -4.242,P = 0.001),查尔森合并症指数≥3分的比例更高(27.0% [48/178] 对17.1% [27/158],χ = 5.384,P = 0.020),手术前接受生物制剂治疗的患者百分比更高(41.0% [73/178] 对16.5% [26/158],χ = 24.285,P < 0.001),尽管手术时间更短(253.8±74.6分钟对315.2±96.8分钟,t = 6.265 < 0.001),但术中失血量更大([中位数,四分位间距]:100.0 [100.0,150.0] ml对50.0 [30.0,100.0] ml,t = -7.054,P < 0.001)。在275例接受TPC - IPAA的患者中,95例(34.6%)有早期并发症(术后30天内),其中20例(7.3%)为Clavien - DindoⅢ - Ⅳ级并发症。在这些患者中,50例(18.2%)有肠梗阻或小肠梗阻,2014 - 2019年组11例,2020 - 2024年组39例;这种差异具有统计学意义(χ = 15.225,P < 0.001)。91例患者(33.1%)有晚期并发症(术后30天以上),75例(27.3%)为袋炎(2014 - 2019年组36例,2020 - 2024年组39例);这种差异无统计学意义(χ = 0.049,P = 0.824)。5例患者(1.8%)接受了袋切除并永久性回肠造口术。在61例接受全结肠或次全结肠切除术的患者中,26例(42.6%)发生早期术后并发症,包括10例(16.4%)Clavien - DindoⅢ - Ⅳ级并发症和1例死亡(1.6%),最后1例归因于多器官功能障碍。3例患者(4.9%)有晚期并发症;2014 - 2019年组和2020 - 2024年组术后并发症发生率的差异无统计学意义(均>0.05)。多变量分析确定术中输血(OR:2.12,95%CI: